Drug Manufacturing

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

BioCryst Pharmaceuticals has secured a $34.7m contract from the US Centers for Disease Control and Prevention (CDC) for the supply of up to 50,000 doses of its approved antiviral influenza therapy, RAPIVAB (peramivir injection) over a five-year period.

Aurobindo to buy parts of Sandoz US from Novartis for $900m

Aurobindo Pharma USA has agreed to acquire selected portions of Sandoz US portfolio from Novartis for $900m of cash and $100m of potential earn-outs.

EUSA Pharma to buy global rights of Janssen’s Sylvant for $115m

UK-based EUSA Pharma has agreed to acquire the global rights of Sylvant (siltuximab), a rare blood disorder drug, from Janssen Sciences Ireland UC for $115m.

Clinigen acquires global rights to Proleukin outside US

Clinigen Group has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Novartis.

US FTC approves Takeda’s $62bn acquisition of Shire

Takeda Pharmaceutical’s £45.3bn ($62bn) acquisition of Shire has been unconditionally approved by the US Federal Trade Commission (FTC).